





Updates from European Renal Association (ERA) Congress 2024 – Outcomes and Clinical Implications of the FLOW Study

 **Monday, 27 May 2024**

 **7:00 PM - 8:00 PM (AEST)**

 **Virtual Event**

The use of GLP-1 agonists are revolutionising the care of type 2 diabetes and cardiovascular disease. Join our panel of experts as they discuss the first in class FLOW study, which investigated the effects of GLP-1 agonists on renal outcomes.

We will be reviewing the FLOW study results presented at the ERA Congress 2024 and their implications for clinical practice in Australia.

Registration is free to attend.

[Register for the webinar](#)



Expert Panel



Professor Vlado Perkovic
MBBS, PhD, FRACP, FASN



Professor Richard Maclsaac
BSc (Hons), MBBS, PhD, FRACP



A/Professor Rathika Krishnasamy
MBBS, FRACP, PhD



Dr Brendon Neuen
MBBS (Hons), MSc, PhD, FRACP, FASN



The ADS gratefully acknowledges the support from Novo Nordisk. This is an independent educational event and Novo Nordisk does not have an influence on the program, speakers or presentations.

